Active ingredient : Semaglutide Used in week 58 of dose escalation (after 0.25 mg) Supports weight loss , appetite suppression, and reduced food cravings Subcutaneous injection in pre-filled FlexTouch pen (4 doses per pen) Mimics GLP-1 hormone to signal fullness and regulate appetite Backed by clinical data for sustained weight reduction and cardiovascular benefit Adolescent and adult use in patients meeting BMI and weight criteria WEGOVY FLEXTOUCH 0.5mg (ITALIAN) Indications The 0.5 mg strength is not a therapeutic dose but an intermediate step to help patients reach the effective maintenance dose (2.4 mg)
class-related risks include acute pancreatitis and gallbladder disease
Warnings and Precautions: Healthcare providers should exercise caution when administering Methylcobalamin, Folic Acid, Niacinamide Injection to patients with renal impairment or hepatic dysfunction, as high doses of certain B vitamins may exacerbate preexisting conditions
Insulin effects in muscle and adipose tissue
Amato MK, Hennessy C, Shah K, Mayer J
By 12 weeks on the medication, that initial fatigue is generally resolved, according to the International Association for Physicians in Aesthetic Medicine